What is it about?
This paper is a description of the development and the properties of an antibody that blocks the terminal complement pathway, that can be used to limit unwanted inflammation in the nervous system. The authors show the exact target where the antibody binds and provide data on in vivo efficacy.
Featured Image
Photo by ANIRUDH on Unsplash
Why is it important?
The ability to control unwanted complement activation is beneficial for diseases where the innate immune system is out of control and causes extra damage to organs. One example is inflammation in the nervous system which is in part initiated by the complement system. The antibody we developed might help to stem this unwanted activation of the innate immune system.
Perspectives
This new antibody that specifically targets C6, offers new opportunities to limit terminal complement activation. Unlike the existing C5 inhibitors that are already available, this new antibody does not interfere with C5a function.
PhD Kees Fluiter
LUMC
Read the Original
This page is a summary of: Development, Characterization, and in vivo Validation of a Humanized C6 Monoclonal Antibody that Inhibits the Membrane Attack Complex, Journal of Innate Immunity, May 2022, Karger Publishers,
DOI: 10.1159/000524587.
You can read the full text:
Contributors
The following have contributed to this page
